{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Overall survival is defined as time from randomization to death or date last known alive.","groups":[{"description":"Patients receive lenalidomide PO QD on days 1-28 and ixazomib citrate PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspirate and/or biopsy and PET and CT scan at screening and on study as well as undergo collection of blood samples throughout the trial.\n\nBiospecimen Collection: Undergo collection of blood samples\n\nBone Marrow Aspirate: Undergo bone marrow aspirate\n\nBone Marrow Biopsy: Undergo bone marrow biopsy\n\nComputed Tomography: Undergo CT scan\n\nIxazomib Citrate: Given PO\n\nLenalidomide: Given PO\n\nQuality-of-Life Assessment: Ancillary studies\n\nQuestionnaire Administration: Ancillary studies","id":"OG000","title":"Arm A (Lenalidomide, Ixazomib Citrate)"},{"description":"Patients receive lenalidomide PO QD on days 1-28 and a placebo PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo bone marrow aspirate and/or biopsy and PET and CT scan at screening and on study as well as undergo collection of blood samples throughout the trial.\n\nBiospecimen Collection: Undergo collection of blood samples\n\nBone Marrow Aspirate: Undergo bone marrow aspirate\n\nBone Marrow Biopsy: Undergo bone marrow biopsy\n\nComputed Tomography: Undergo CT scan\n\nLenalidomide: Given PO\n\nPlacebo Administration: Given PO\n\nPositron Emission Tomography: Undergo PET scan\n\nQuality-of-Life Assessment: Ancillary studies\n\nQuestionnaire Administration: Ancillary studies","id":"OG001","title":"Arm B (Lenalidomide, Placebo)"}],"populationDescription":"Only one patient was enrolled on this study. Due to the concern on confidentiality, individual data is not reported.","reportingStatus":"POSTED","timeFrame":"Assessed every 3 months if patient is <2 years from randomization, every 6 months if patient is 2-5 years from randomization, annually if patient is 5 years or more from randomization.","title":"Overall Survival (OS)","type":"PRIMARY"}